Among patients with relapsed or refractory multiple myeloma, Tecvayli (teclistamab-cqyv) monotherapy was associated with a 71 ...

The T cell receptor (TCR)-CD3 complex is crucial to adaptive immunity, driving antigen recognition and intracellular signaling cascades. CD3 subunits harbor key cytoplasmic motifs that recruit ...

The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...

Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference Reaching more metastatic uveal melanoma patients with KIMMTRAK (tebentafusp) in 2026 through US ...

As of Wednesday, January 07, CytomX Therapeutics, Inc.’s CTMX share price has surged by 6.40%, which has investors questioning if this is right time to sell.

At ASH 2025, investigators reported early results from the first-in-human phase 1 inMMyCAR study evaluating KLN-1010, an investigational in vivo gene ...

SOUTH SAN FRANCISCO, Calif. and MONROVIA, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel ...

The teclistamab-daratumumab combination shows an 83.4% progression-free survival rate after three years, suggesting a potential functional cure for multiple myeloma. The MajesTEC-3 trial indicates tec ...

Explore groundbreaking therapies for type 1 diabetes that aim to delay onset, preserve β-cell function, and restore insulin independence. Type 1 diabetes (T1D) is an idiopathic, autoimmune disease ...

Janssen's Tecvayli (teclistamab) and Pfizer's Elrexfio (elanatumab), dual-specific antibodies with the same mechanism approved for multiple myeloma treatment, have cleared the first hurdle for ...

First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein Two MDX2004 abstracts accepted for poster presentation at SITC Annual Meeting 2025 WESTON, ...